Zimbabwe has turned down a major US health deal valued at $367m (£272m) spanning five years because of Washington's request for confidential data.
The decision became public after a government memo from December was disclosed, indicating that President Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesman later clarified that the US was seeking biological samples for scientific study and commercial purposes while was not willing to guarantee the resulting advantages from future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged more dialogue to reach a agreement acceptable to both sides so the country's critical HIV treatment initiative can be sustained.
Wider Background
This rejection comes after a similar case in Kenya, where a court suspended a related deal with the US following concerns were filed about the safety of citizens' medical information.
After returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing direct bilateral deals to enhance openness and accountability.
According to reports, 16 African countries have so far agreed to these new health pacts, constituting over $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration might have yielded extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment through US-supported programmes," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, without any corresponding promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"In essence, our country would supply the raw materials for medical research without any certainty that the final treatments would be accessible to our population if a future disease outbreak emerge."
National Interest and Global Health
He also noted that the American exit from the global health body and its push of bilateral deals were undermining systems previously set up via the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This framework is designed to guarantee that when a country contributes its samples, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the resources to develop them."
These objections over the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage ongoing dialogue with our US partners on how subsequent collaboration could be designed in a manner that respects the sovereignty and interests of each country."
Health Experts Response
Medical experts stated it recognised the official position, but suggested that talks must proceed considering a large portion of the nation's Aids initiatives depended on foreign aid.
"In cases where specific concerns exist, including those involving information security or implementation frameworks, these can often be addressed via detailed discussion and mutually agreed protections," it commented.
The halted deal underscores the ongoing debate between accepting much-needed international aid and safeguarding local interests in an increasingly interconnected world.